Dihydroergotamine Intranasal Powder for Acute Migraine Treatment

The design and pharmacokinetic properties of DHE intranasal powder appear to offer advantages over other DHE dosage forms, but current data do not support its use as a first-line agent for the treatment of migraine headaches.

Authors

Chris M. Terpening (ORCID: https://orcid.org/0000-0003-3764-5171)
Jon P. Wietholter (ORCID: https://orcid.org/0000-0002-4364-3909)

Institutions

West Virginia University (US)
University of Charleston (US)

Publication Details

Journal: Annals of Pharmacotherapy
Published: 2025-12-04
DOI: https://doi.org/10.1177/10600280251388440
Primary Topic: Migraine and Headache Studies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Dihydroergotamine Intranasal Powder for Acute Migraine Treatment

Chris M. Terpening, Jon P. Wietholter

Dec 4, 2025

Annals of Pharmacotherapy

Migraine and Headache Studies

article

Dihydroergotamine Intranasal Powder for Acute Migraine Treatment

Chris M. Terpening, Jon P. Wietholter

December 4, 2025article en

Abstract

Annals of Pharmacotherapy

West Virginia University (US), University of Charleston (US)

Openalex Percentile: Top 55%

Migraine and Headache Studies

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Dihydroergotamine Intranasal Powder for Acute Migraine Treatment — Chris M. Terpening, Jon P. Wietholter · Annals of Pharmacotherapy (2025) | TGRS Research Map | TGRS